Calidi Biotherapeutics to file IND for CLD-401 in Q4 2026.
ByAinvest
Thursday, Jan 29, 2026 6:02 am ET1min read
CLDI--
Calidi Biotherapeutics plans to file an IND for its first RedTail lead candidate, CLD-401, in Q4 2026. The company expects to present proof-of-concept data for the RedTail platform in oncology and non-oncology indications, and expanding its platform with new payloads. Calidi aims to demonstrate the versatility of the RedTail platform in delivering high concentrations of IL-15 superagonist to the tumor microenvironment.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet